AU2019328290B2 - Multi-chain chimeric polypeptides and uses thereof - Google Patents

Multi-chain chimeric polypeptides and uses thereof Download PDF

Info

Publication number
AU2019328290B2
AU2019328290B2 AU2019328290A AU2019328290A AU2019328290B2 AU 2019328290 B2 AU2019328290 B2 AU 2019328290B2 AU 2019328290 A AU2019328290 A AU 2019328290A AU 2019328290 A AU2019328290 A AU 2019328290A AU 2019328290 B2 AU2019328290 B2 AU 2019328290B2
Authority
AU
Australia
Prior art keywords
amino acids
rule
substitute sheet
tgfrs
tissue factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019328290A
Other languages
English (en)
Other versions
AU2019328290A1 (en
Inventor
Hing Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunitybio Inc
Original Assignee
Immunitybio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunitybio Inc filed Critical Immunitybio Inc
Publication of AU2019328290A1 publication Critical patent/AU2019328290A1/en
Assigned to IMMUNITYBIO, INC. reassignment IMMUNITYBIO, INC. Request for Assignment Assignors: HCW Biologics, Inc.
Application granted granted Critical
Publication of AU2019328290B2 publication Critical patent/AU2019328290B2/en
Priority to AU2024287134A priority Critical patent/AU2024287134A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
AU2019328290A 2018-08-30 2019-08-29 Multi-chain chimeric polypeptides and uses thereof Active AU2019328290B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024287134A AU2024287134A1 (en) 2018-08-30 2024-12-21 Multi-chain chimeric polypeptides and uses there

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US201862725043P 2018-08-30 2018-08-30
US201862724969P 2018-08-30 2018-08-30
US201862725010P 2018-08-30 2018-08-30
US62/725,043 2018-08-30
US62/724,969 2018-08-30
US62/725,010 2018-08-30
US201862746832P 2018-10-17 2018-10-17
US62/746,832 2018-10-17
US201862749007P 2018-10-22 2018-10-22
US62/749,007 2018-10-22
US201862749506P 2018-10-23 2018-10-23
US62/749,506 2018-10-23
US201962816683P 2019-03-11 2019-03-11
US62/816,683 2019-03-11
US201962817241P 2019-03-12 2019-03-12
US201962817230P 2019-03-12 2019-03-12
US62/817,230 2019-03-12
US62/817,241 2019-03-12
US201962881088P 2019-07-31 2019-07-31
US62/881,088 2019-07-31
PCT/US2019/048881 WO2020047299A1 (en) 2018-08-30 2019-08-29 Multi-chain chimeric polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024287134A Division AU2024287134A1 (en) 2018-08-30 2024-12-21 Multi-chain chimeric polypeptides and uses there

Publications (2)

Publication Number Publication Date
AU2019328290A1 AU2019328290A1 (en) 2021-02-25
AU2019328290B2 true AU2019328290B2 (en) 2024-10-10

Family

ID=67928938

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019328290A Active AU2019328290B2 (en) 2018-08-30 2019-08-29 Multi-chain chimeric polypeptides and uses thereof
AU2024287134A Pending AU2024287134A1 (en) 2018-08-30 2024-12-21 Multi-chain chimeric polypeptides and uses there

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024287134A Pending AU2024287134A1 (en) 2018-08-30 2024-12-21 Multi-chain chimeric polypeptides and uses there

Country Status (11)

Country Link
US (8) US11518792B2 (enExample)
EP (2) EP3844181B1 (enExample)
JP (3) JP7397874B2 (enExample)
KR (2) KR20250160211A (enExample)
CN (1) CN112996805A (enExample)
AU (2) AU2019328290B2 (enExample)
CA (1) CA3108949A1 (enExample)
IL (1) IL280918B2 (enExample)
SG (1) SG11202101779RA (enExample)
TW (1) TWI851594B (enExample)
WO (1) WO2020047299A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
IL272635B2 (en) 2017-09-06 2024-02-01 Univ Yale Variants of interleukin-18 and methods of use
CN112996805A (zh) 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
EP3843788A1 (en) 2018-08-30 2021-07-07 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CN120365435A (zh) 2018-08-30 2025-07-25 免疫生物公司 单链嵌合多肽和多链嵌合多肽以及其用途
US20220002370A1 (en) 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
JP7713393B2 (ja) * 2019-06-21 2025-07-25 イミュニティーバイオ インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
EP4103599A1 (en) 2020-02-11 2022-12-21 HCW Biologics, Inc. Methods of activating regulatory t cells
US12115191B2 (en) 2020-02-11 2024-10-15 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
KR20220140535A (ko) * 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 크로마토그래피 수지 및 이의 용도
EP4143231A1 (en) 2020-04-29 2023-03-08 HCW Biologics, Inc. Anti-cd26 proteins and uses thereof
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
EP4157460A1 (en) * 2020-06-01 2023-04-05 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) * 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
USD986799S1 (en) * 2020-09-11 2023-05-23 Wind Craft Aviation Inc. Aircraft
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
GB202102049D0 (en) * 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
CN117120075A (zh) 2021-02-17 2023-11-24 库拉治疗股份有限公司 抗病原体白细胞介素-TGF-β受体融合多肽
JP2024529494A (ja) * 2021-07-30 2024-08-06 クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド 抗原ターゲティング、抗ｃｄ１６ａおよび免疫エフェクター細胞活性化の三機能性融合タンパク質ならびにその応用
IL310164A (en) * 2021-08-11 2024-03-01 Hcw Biologics Inc Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases
CN114042154B (zh) * 2021-12-14 2024-08-16 澳门大学 一种药物组合在制备抗肿瘤的联合治疗药物中的应用
WO2023134716A1 (zh) * 2022-01-14 2023-07-20 盛禾(中国)生物制药有限公司 一种结合b7h3和nkp30的双特异性抗体及其应用
WO2023168363A1 (en) * 2022-03-02 2023-09-07 HCW Biologics, Inc. Method of treating pancreatic cancer
US20240075141A1 (en) 2022-03-18 2024-03-07 WUGEN, Inc. Chimeric receptor constructs for nk cells
US20230330228A1 (en) 2022-03-22 2023-10-19 WUGEN, Inc. Hybrid promoters, vectors containing same and methods of use
EP4507711A1 (en) 2022-04-13 2025-02-19 ImmunityBio, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
JP7610308B2 (ja) * 2022-06-29 2025-01-08 メスキュージェナシス株式会社 ペプチド及び該ペプチドを含む会合体又は組成物
WO2025054489A1 (en) * 2023-09-08 2025-03-13 The Regents Of The University Of California Chimeric antigen receptors with card domains
US20250134974A1 (en) * 2023-10-31 2025-05-01 Immunitybio, Inc. Multi-chain chimeric polypeptides and use thereof in the treatment of advanced solid tumors
CN117924505B (zh) * 2024-03-25 2024-09-13 青岛宝迈得生物科技有限公司 一种重组hdac2蛋白单克隆抗体及其应用
WO2026043906A1 (en) * 2024-08-19 2026-02-26 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
US20260049118A1 (en) * 2024-08-19 2026-02-19 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CN120289652B (zh) * 2025-04-16 2026-02-13 广东拓普灵生物医药科技有限公司 一种nk细胞的制备方法及其在肿瘤免疫治疗中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018075989A1 (en) * 2016-10-21 2018-04-26 Altor Bioscience Corporation Multimeric il-15-based molecules

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE69519929T2 (de) 1994-07-11 2001-05-23 Board Of Regents, The University Of Texas System Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
US6117980A (en) 1997-02-21 2000-09-12 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
AU2270101A (en) 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
AU2001239470A1 (en) 2000-02-24 2001-09-03 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
DK1345969T3 (da) 2000-12-26 2010-11-29 Inst Nat Sante Rech Med Anti-CD28-antistof
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
WO2003015697A2 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
TWI338009B (en) 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
AU2003239197A1 (en) 2002-06-07 2003-12-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Novel stable anti-cd22 antibodies
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
KR20120068769A (ko) * 2002-07-15 2012-06-27 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
US7482436B2 (en) 2002-08-30 2009-01-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of antibody
EP1400534B1 (en) 2002-09-10 2015-10-28 Affimed GmbH Human CD3-specific antibody with immunosuppressive properties
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
EP1599502A1 (en) 2003-02-27 2005-11-30 TheraVision GmbH A molecule which binds cd80 and cd86
CA2518854A1 (en) 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor
US7618632B2 (en) 2003-05-23 2009-11-17 Wyeth Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
US9005613B2 (en) 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
JP2005124568A (ja) 2003-10-01 2005-05-19 Junichi Masuyama 細胞活性化方法及びこれを用いる細胞製造方法並びに医薬組成物
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
ES2375481T3 (es) 2004-03-30 2012-03-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticuerpos biespecíficos para elegir como diana células que participan en reacciones de tipo alérgico, composiciones y usos de los mismos.
TR201901929T4 (tr) 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
US7393833B2 (en) * 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
DK1863905T3 (en) 2005-03-17 2016-04-04 Ucl Business Plc PROCEDURE FOR ACTIVATING NATURAL KILLER CELLS USING VITRO TUMOR CELL PREPARATIONS
CN100509849C (zh) 2005-04-07 2009-07-08 苏州大学 可溶性人cd28分子检测试剂盒及其应用
JP5122441B2 (ja) 2005-04-19 2013-01-16 シアトル ジェネティックス， インコーポレイテッド ヒト化抗ｃｄ７０結合剤およびその使用
CA2763671A1 (en) 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
CA2607954A1 (en) 2005-05-11 2006-11-16 Philogen S.P.A. Conjugate for targeting of drug
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP2604279A1 (en) 2008-03-27 2013-06-19 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
BRPI0914251B1 (pt) 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
WO2010017103A2 (en) 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2011028811A2 (en) 2009-09-01 2011-03-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130036192A (ko) 2010-02-11 2013-04-11 알렉시온 파마슈티칼스, 인코포레이티드 항-ｃｄ200 항체들을 이용한 치료 및 진단 방법
EP2560994B1 (en) 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
AU2011262758B8 (en) 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
JP2012034668A (ja) 2010-08-12 2012-02-23 Tohoku Univ ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用
US8507222B2 (en) * 2010-09-21 2013-08-13 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
EP2627425A4 (en) 2010-10-11 2014-11-05 Abbvie Inc METHODS OF PURIFYING PROTEINS
CN102153653B (zh) 2010-12-30 2012-08-15 厦门大学 肿瘤血管靶向多肽与组织因子的融合蛋白及其制备方法
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
US8476409B2 (en) 2011-04-19 2013-07-02 Merrimack Pharmaceuticals, Inc. Bispecific anti-IGF-1R and anti-ErbB3 antibodies
WO2012147713A1 (ja) 2011-04-25 2012-11-01 第一三共株式会社 抗ｂ７－ｈ３抗体
ES2765874T3 (es) 2011-05-25 2020-06-11 Innate Pharma Sa Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
US8753640B2 (en) 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
CN103732623B (zh) 2011-06-03 2017-09-29 佐马技术有限公司 对TGF‑β具有特异性的抗体
WO2012170470A1 (en) 2011-06-06 2012-12-13 Board Of Regents Of The University Of Nebraska Compositions and methods for detection and treatment of cancer
ES2677367T3 (es) 2011-06-22 2018-08-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos anti-Axl y usos de los mismos
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
TWI495644B (zh) 2011-11-11 2015-08-11 Rinat Neuroscience Corp 營養層細胞表面抗原（Ｔｒｏｐ－２）之專一性抗體類及彼等之用途
EP2807292B1 (en) 2012-01-26 2019-05-22 Tecan Genomics, Inc. Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation
CA2866378A1 (en) 2012-03-08 2013-09-12 Selig Sealing Products, Inc. Container sealing member with protected security component and removal tab
KR101535341B1 (ko) 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
PE20150645A1 (es) 2012-08-08 2015-05-11 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas
WO2014026054A2 (en) 2012-08-10 2014-02-13 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
CN104379169A (zh) 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
EP2890713A1 (en) 2012-08-28 2015-07-08 Institut Curie Cluster of differentiation 36 (cd36) as a therapeutic target for hiv infection
DK3199552T3 (da) 2012-11-20 2020-03-30 Sanofi Sa Anti-ceacam5-antistoffer og anvendelser heraf
EP2931750B8 (en) 2012-12-17 2021-11-03 Cell Medica Inc. Antibodies against il-1 beta
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
US9790274B2 (en) 2013-03-14 2017-10-17 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
JP2015030666A (ja) 2013-07-31 2015-02-16 学校法人順天堂 抗ヒトｃｄ２６モノクローナル抗体又はその抗原結合性断片
CN103709251B (zh) 2013-12-19 2016-04-13 江苏众红生物工程创药研究院有限公司 全人源抗cd26抗体及其应用
KR102127408B1 (ko) 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
MX2016009690A (es) 2014-02-03 2017-03-03 Nat Cancer Ct Anticuerpos monoclonal anti-factor de tejido.
FR3021970B1 (fr) 2014-06-06 2018-01-26 Universite Sciences Technologies Lille Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MD4733C1 (ro) 2014-08-19 2021-07-31 Merck Sharp & Dohme Corp Anticorpi anti-TIGIT
DK3186283T3 (da) 2014-08-29 2020-03-02 Hoffmann La Roche Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1
CA2972048C (en) 2014-12-22 2023-03-07 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
CN108064245A (zh) 2015-04-17 2018-05-22 埃尔萨里斯生物技术公司 抗Tyro3抗体及其用途
KR101778439B1 (ko) 2015-04-27 2017-09-14 울산대학교 산학협력단 자연살해세포 활성화제를 유효성분으로 함유하는 면역증강 및 항암활성증진용 조성물
US10723793B2 (en) 2015-06-12 2020-07-28 Ludwig Institute For Cancer Research, Ltd. TGF-β3 specific antibodies and methods and uses thereof
PT3328894T (pt) 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
JP6931228B2 (ja) 2015-09-11 2021-09-01 ワイズ・エー・シー株式会社 抗ｃｄ２６抗体と他の抗癌剤とを組み合わせた癌治療用組成物
PE20181046A1 (es) 2015-09-25 2018-07-03 Genentech Inc Anticuerpos anti-tigit y metodos de uso
EP3373970A4 (en) 2015-11-13 2019-07-10 Dana Farber Cancer Institute, Inc. NKG2D IG FUSION PROTEIN FOR CANCER IMMUNOTHERAPY
AU2017219254B2 (en) 2016-02-17 2019-12-12 Novartis Ag TGFbeta 2 antibodies
CA3015619A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
WO2017189526A1 (en) 2016-04-25 2017-11-02 Musc Foundation For Research Development Activated cd26-high immune cells and cd26-negative immune cells and uses thereof
DK3523416T3 (da) 2016-10-05 2025-03-03 Univ Central Florida Res Found Inc Fremgangsmåder og sammensætninger relateret til nk-celle- og anti-pdl1-kræftbehandlinger
US20210230221A1 (en) 2017-01-03 2021-07-29 Bioatla, Llc Protein therapeutics for treatment of senescent cells
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
AU2018226526B2 (en) 2017-02-28 2025-03-13 Affimed Gmbh Combination of an anti-CD16A antibody with a cytokine
KR102867975B1 (ko) 2017-03-06 2025-10-14 알토 바이오사이언스 엘엘씨 Il-12 및 il-18로의 il-15-기반 융합
KR20190126182A (ko) 2017-03-27 2019-11-08 난트셀, 인크. aNK 및 IL-12 조성물 및 방법 (ANK AND IL-12 COMPOSITIONS AND METHODS)
EP3421607A1 (en) 2017-06-29 2019-01-02 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Identification and elimination of damaged and/or senescent cells
JP2020533971A (ja) 2017-08-28 2020-11-26 アルター・バイオサイエンス・コーポレーション Ｉｌ−１５をベースとするｉｌ−７及びｉｌ−２１への融合物
CN112996805A (zh) 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
EP3843788A1 (en) 2018-08-30 2021-07-07 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CN120365435A (zh) 2018-08-30 2025-07-25 免疫生物公司 单链嵌合多肽和多链嵌合多肽以及其用途
JP7713393B2 (ja) 2019-06-21 2025-07-25 イミュニティーバイオ インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
KR20220140535A (ko) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 크로마토그래피 수지 및 이의 용도
EP4103599A1 (en) 2020-02-11 2022-12-21 HCW Biologics, Inc. Methods of activating regulatory t cells
US12115191B2 (en) 2020-02-11 2024-10-15 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
EP4143231A1 (en) 2020-04-29 2023-03-08 HCW Biologics, Inc. Anti-cd26 proteins and uses thereof
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
EP4507711A1 (en) 2022-04-13 2025-02-19 ImmunityBio, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018075989A1 (en) * 2016-10-21 2018-04-26 Altor Bioscience Corporation Multimeric il-15-based molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALTER, S. ET AL., 'Targeted IL-15-based Protein Fusion Complexes as Cancer Immunotherapy Approaches', J Immunol Sci. January 16, 2018, Vol.2, No:1, pages 15-18 *

Also Published As

Publication number Publication date
JP2024026248A (ja) 2024-02-28
AU2019328290A1 (en) 2021-02-25
US20230128292A1 (en) 2023-04-27
EP3844181B1 (en) 2025-11-12
JP2025172844A (ja) 2025-11-26
WO2020047299A1 (en) 2020-03-05
TW202122416A (zh) 2021-06-16
EP3844181A1 (en) 2021-07-07
US12269854B2 (en) 2025-04-08
IL280918B2 (en) 2025-10-01
IL280918B1 (en) 2025-06-01
AU2024287134A1 (en) 2025-01-23
US11884712B2 (en) 2024-01-30
US20230272027A1 (en) 2023-08-31
US20240132561A1 (en) 2024-04-25
CN112996805A (zh) 2021-06-18
TW202442672A (zh) 2024-11-01
EP3844181C0 (en) 2025-11-12
US20240124543A1 (en) 2024-04-18
JP2021534828A (ja) 2021-12-16
JP7735373B2 (ja) 2025-09-08
US12509494B2 (en) 2025-12-30
KR20210070287A (ko) 2021-06-14
IL280918A (en) 2021-04-29
US11518792B2 (en) 2022-12-06
US20200071374A1 (en) 2020-03-05
US20210070826A1 (en) 2021-03-11
US20240124544A1 (en) 2024-04-18
SG11202101779RA (en) 2021-03-30
US20210070825A1 (en) 2021-03-11
EP4659757A2 (en) 2025-12-10
CA3108949A1 (en) 2020-03-05
NZ772550A (en) 2025-08-29
TWI851594B (zh) 2024-08-11
US12398186B2 (en) 2025-08-26
KR102877278B1 (ko) 2025-11-03
EP4659757A3 (en) 2026-01-14
KR20250160211A (ko) 2025-11-11
JP7397874B2 (ja) 2023-12-13

Similar Documents

Publication Publication Date Title
AU2019328290B2 (en) Multi-chain chimeric polypeptides and uses thereof
WO2023020621A1 (en) Anti-ccr8 antibodies and uses thereof
TW202112804A (zh) 多特異性蛋白質
WO2018026819A2 (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
US20250000946A1 (en) Il-2 variants and fusion proteins thereof
KR20220150274A (ko) Il-7 단백질과 이중특이적 항체의 조합물을 사용한 종양의 치료 방법
TWI916895B (zh) 多鏈嵌合多肽及其用途
KR20230098201A (ko) 줄기 세포 동원의 유도 방법
WO2024199458A1 (en) Il-2 variants with improved stability and compositions thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: IMMUNITYBIO, INC.

Free format text: FORMER APPLICANT(S): HCW BIOLOGICS, INC.

FGA Letters patent sealed or granted (standard patent)